Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTX-LDE (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
- Development stage
- Unknown
- Lead developer
- University of Sao Paulo General Hospital
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
MTX-LDE is an investigational nanomedicine formulation consisting of methotrexate (MTX) incorporated into lipid core nanoparticles (LDE) that mimic the structure of low-density lipoprotein (LDL). Developed by researchers at the University of São Paulo General Hospital, the formulation is designed to target inflammatory sites by binding to LDL receptors, which are often overexpressed in inflamed tissues. Methotrexate, the active ingredient, is a folate analogue that inhibits dihydrofolate reductase, providing anti-inflammatory and immunosuppressive effects. By using the LDE delivery system, the drug aims to enhance cellular uptake and reduce the systemic toxicity typically associated with methotrexate. It has been evaluated in Phase 1/2 clinical trials for the treatment of hospitalized patients with COVID-19 to mitigate the associated inflammatory response.
- Other names
- methotrexate-loaded lipid nanoparticlesmethotrexate-LDENano-COVID19Nano-COVID-19Nano-COVID 19
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)APOE (Apolipoprotein E)DHFR (Dihydrofolate reductase)LDLR (Low-density lipoprotein receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on MTX-LDE (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTX-LDE (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo).